As of today, the list of publicly announced RMAT’s has risen to 30. However, the U.S. FDA states it has received 108 total requests for RMAT designations and granted 40.
RMAT stands for “Regenerative Medicine Advanced Therapy” designation. Sponsors of cell and gene therapies are eligible to obtain an RMAT designation from the U.S. FDA if their product is intended to treat serious or life-threatening diseases and there is preliminary clinical evidence that it can address unmet medical needs.
In this article:
- RMAT List
- RMAT Reviews by The FDA
- Regenerative Medicine Advanced Therapy (RMAT)
- RMAT Definition
- Future RMAT Designations
To date, 30 RMAT designations have been publicly announced (see table below). The most recent additions were Krystal Biotech’s RMAT designation for KB103 on June 24, 2019 and Sangamo Therapeutics’ RMAT designation for SB-525 on July 5, 2019.
However, the U.S. FDA states that additional RMATs have been awarded, making the total number even higher.
|COMPANY||PRODUCT NAME||INDICATION||DATE OF APPROVAL|
|Abeona Therapeutics||EB-101||Recessive RDEB||1/29/2018|
|Abeona Therapeutics||ABO-102||Sanfilippo Syndrome Type A (MPS IIIA)||4/23/2018|
|Allovir||Viralym-M (ALVR105)||BK Virus-associated Hemorrhagic Cystitis after HSC Transplant||6/11/2019|
|Asterias Biotherapeutics||AST-OPC1||Spinal Cord Injury (SCI)||10/2/2017|
|Audentes Therapeutics||AT132||X-linked Myotubular Myopathy (XLMTM)||8/21/2018|
|AxoGen, Inc.||Avance® Nerve Graft||Peripheral nerve repair||10/29/2018|
|bluebird bio||LentiGlobin||Severe Sickle Cell Disease||10/1/2017|
|Caladrius Biosciences||CLBS14 (CD34+ cell therapy program)||Refractory angina||6/19/2018|
|Capricor Therapeutics||CAP-1001||Duchenne muscular dystrophy (DMD)||2/5/2018|
|Cellerant Therapeutics||Romyelocel-L||Prevention of Infections During Neutropenia||7/2/2018|
|Cellvation Inc. (Fortress Biotech Co.)||CEVA101||Traumatic Brain Injury (TBI)||11/8/2017|
|ExCellThera||ECT-001||Hematologic Malignancies||Tuesday, April 23, 2019|
|Humacyte||Humacyl||Vascular Access for Hemodialysis||3/20/2017|
|jCyte||jCell||Retinitis Pigmentosa (RP)||5/2/2017|
|Juno Therapeutics||JCAR017||Lymphoma (large B cell NHL)||11/1/2017|
|Krystal Biotech||KB103||Wound Closure (RDEB patients)||06/24/2019|
|Mallinckrodt Pharmaceuticals||Stratagraft||Thermal Burns||7/18/2017|
|Mesoblast, Ltd.||MPC-150-IM||Heart Failure||12/21/2017|
|MiMedx Group||AmnioFix® Injectable||Knee Osteoarthritis (OA)||3/9/2018|
|Nightstar Therapeutics||NSR-REP1||Choroideremia (progressive vision loss)||6/14/2018|
|Poseida Therapeutics||P-BCMA-101||Relapsed/Refractory Multiple Myeloma||11/5/2018|
|Rocket Pharmaceuticals||RP-L102||Fanconi Anemia||11/27/2018|
|Sangamo Therapeutics||SB-525||Severe Hemophilia A||070/05/2019|
|Talaris||FCR-001||Preventing Renal Transplantation Rejection||4/18/2019|
|Vericel Corporation||Ixmyelocel-T||Dilated Cardiomyopathy||5/10/2017|
|Voyager Therapeutics||VY-AADC||Advanced Parkinson’s disease||6/21/2018|
Total RMATs Received and Awarded by FDA
To date, the U.S. FDA has received 108 total requests for RMAT designations and granted 40. This means that slightly over one-third of all RMAT applications get approved.
The table below presents the cumulative number of RMAT requests that the FDA has received by year.
*Source: U.S. FDA
Regenerative Medicine Advanced Therapy (RMAT)
RMAT is an acronym that stands for “Regenerative Medicine Advanced Therapy”. Introduced in December 2016 as part of the 21st Century Cures Act, an RMAT designation can shorten time to market for innovative medicines.
An RMAT submission request must be made in conjunction with an Investigational New Drug application (IND), either concurrently or as an amendment to an existing IND.
Products eligible for an RMAT designation include:
- Cell therapies
- Gene therapies
- Therapeutic tissue engineering products
- Human cell and tissue products
- Combination products using such therapies or products
By definition, an RMAT is an award from the U.S. FDA that allows for faster, more streamlined approvals of regenerative medicine products within the United States, such as cell and gene therapies, tissue engineering products, and combination products. RMAT designations make innovative products eligible for quicker development and review of a marketing application.
An RMAT designation is similar to the breakthrough therapy designation that is available to drugs.
Benefits of an RMAT include increased opportunities to meet with FDA officials, as well as early meetings to discuss potential surrogate or intermediate endpoints.
21st Century Cures Act
The 21st Century Cures Act was passed by the 114th U.S. Congress in December 2016. The act authorize $6.3 billion in funding, most of which is allocated for the National Institutes of Health (NIH).
The bill, passed by both houses of Congress and signed into law by President Obama, puts the U.S. on the same playing field as other countries that support accelerated of innovative medicines. Other regions that have accelerated pathways include Japan, South Korea, and the EU. The bill encourages late-stage development in regenerative medicine, recognizing the field’s potential to address severe unmet medical needs.
Congress included several provisions related to cell and gene therapies in the 21st Century Cures Act, the most important of which is the RMAT designation.
Regenerative Medicine Advanced Therapy Reviews by The FDA
For more detail, the following is from the U.S. FDA website:
As described in Section 3033 of the 21st Century Cures Act, a drug is eligible for regenerative medicine advanced therapy (RMAT) designation if:
- The drug is a regenerative medicine therapy, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, except for those regulated solely under Section 361 of the Public Health Service Act and part 1271 of Title 21, Code of Federal Regulations;
- The drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and
- Preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such disease or condition.
Future RMAT Designations
There is also chatter within the industry that Tigenix will apply for an RMAT designation for Cx601, a local administration of expanded adipose-derived stem cells (eASCs).
Want a continuously updated, searchable, sortable Excel database of RMAT designations that you can use on-the-go?
Claim your RMAT Database now and get Free Updates for the next 12 months as new RMAT’s are added.
Who do you expect to appear next on this RMAT list? Mention them in the comments below.